Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00193024
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193167
- Locations
- ๐บ๐ธ
Tennessee Oncology, Nashville, Tennessee, United States
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193141
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00193518
- Locations
- ๐บ๐ธ
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00193271
- Locations
- ๐บ๐ธ
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00193011
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193297
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193505
- Locations
- ๐บ๐ธ
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00193219
- Locations
- ๐บ๐ธ
St. Louis Cancer Care, Chesterfield, Missouri, United States
๐บ๐ธJackson Oncology Associates, Jackson, Mississippi, United States
๐บ๐ธChattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 123
- Registration Number
- NCT00193206
- Locations
- ๐บ๐ธ
Florida Cancer Specialists, Fort Myers, Florida, United States
๐บ๐ธOncology Hematology Care, Cincinnati, Ohio, United States
๐บ๐ธTennessee Oncology, Nashville, Tennessee, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath